{"id":198566,"name":"ASTRAZENECA PHARMACEUTICALS LP","slug":"astrazeneca-pharmaceuticals-lp","state":"DE","description":"&#226;€‹Biopharmaceutical Company.","totalSpending":1160000,"filings":18,"yearlySpending":[{"year":2019,"income":200000},{"year":2020,"income":240000},{"year":2021,"income":240000},{"year":2022,"income":320000},{"year":2025,"income":160000}],"firms":["TODD STRATEGY GROUP"],"lobbyists":["DANIEL TODD","PAUL EDATTEL","JEFF LUCAS","TAYLOR SEXTON","ERIC BERGREN","KATHERINE COTTON","TED LEHMAN"],"issues":["PHA","HCR","MMM"],"sampleDescriptions":["Drug pricing.","COVID-19 Response.","COVID-19 response.","COVID-19 response.\nH.R.5376 - Build Back Better Act.\nH.R.3684 - Infrastructure Investment and Jobs Act.","Drug pricing. COVID-19 Response.","Issues related to the 340B drug discount program.","Drug Pricing. COVID-19 Response. General issues related to rare disease and orphan drugs. Reauthorization of the FDA User Fee Act. General issues related to diagnostics for patients with rare diseases. Items related to the Administrations Cancer Moonshot. Prescription Drug User Fee Act (PDUFA).","General issues related to patient access to rare disease therapies, Part B and Part D drugs. Issues related to home infusion for Part B patients.","340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.","340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies.","General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.","340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.","General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy."],"years":[2019,2020,2021,2022,2025]}